問卷

TPIDB > Search Result

Search Result

篩選

List

27Cases

2020-08-31 - 2027-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2020-10-15 - 2027-09-01

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2022-07-01 - 2028-05-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2023-06-02 - 2030-12-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2023-10-01 - 2033-02-05

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2025-03-31 - 2028-01-31

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2025-11-07 - 2029-09-25

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2025-11-01 - 2027-08-22

Phase II

Active
A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
  • Condition/Disease

    Drug-Related Side Effects and Adverse Reactions

  • Test Drug

    皮下注射劑

Participate Sites
5Sites

Recruiting5Sites

2025-04-01 - 2032-12-31

Active
A phase 3, multicenter, double-blind, placebo-controlled trial evaluating the efficacy and safety of olomorisabin in combination with standard-of-care immunotherapy in participants with resected or unresectable KRAS G12C-mutant non-small cell lung cancer – SUNRAY-02
  • Condition/Disease

    Part A: Does adding olomorasib to pembrolizumab, compared to placebo and pembrolizumab, prolong disease-free survival (DFS) in participants with pathologically confirmed resected stage II-IIIB NSCLC? (These participants had a KRAS G12C mutation, PD-L1 performance ranging from 0% to 100%, and had previously received chemotherapy.) Part B: Does adding olomorasib to durvalumab, compared to placebo and durvalumab, prolong disease-free survival (PFS) in participants with pathologically confirmed unresectable stage III non-small cell lung cancer? (These participants had a KRAS G12C mutation, had not experienced disease progression after concurrent platinum-based chemotherapy and radiation therapy, and had PD-L1 performance ranging from 0% to 100%.)

  • Test Drug

    Durvalumab Olomorasib PembrolizumabDurvalumab

Participate Sites
18Sites

Recruiting18Sites

1 2 3